(Q38631404)

4 September 2017

title

The role of hypoxia in pancreatic cancer: a potential therapeutic target? (English)

1 reference

4 September 2017

1 reference

1

Mert Erkan

1 reference

4 September 2017

Metin Kurtoglu

2

1 reference

4 September 2017

Jorg Kleeff

series ordinal

3

1 reference

4 September 2017

publication date

11 November 2015

1 reference

Expert Review of Gastroenterology & Hepatology

4 September 2017

published in

1 reference

4 September 2017

volume

10

1 reference

4 September 2017

issue

3

1 reference

4 September 2017

page(s)

301-316

1 reference

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Whole genomes redefine the mutational landscape of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Very Long-term Survival Following Resection for Pancreatic Cancer Is Not Explained by Commonly Mutated Genes: Results of Whole-Exome Sequencing Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

RUNX3 Controls a Metastatic Switch in Pancreatic Ductal Adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Distant metastasis occurs late during the genetic evolution of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Hypoxia in cancer: significance and impact on clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Detection and characterization of tumor hypoxia using pO2 histography

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Analysis of the intra- and intertumoral heterogeneity of hypoxia in pancreatic cancer patients receiving the nitroimidazole tracer pimonidazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Tumor microenvironmental physiology and its implications for radiation oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Gray-scale and color flow sonography of pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Cancer-stellate cell interactions perpetuate the hypoxia-fibrosis cycle in pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Pigment epithelium-derived factor associates with neuropathy and fibrosis in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Tumour necrosis is a postoperative prognostic marker for pancreatic cancer patients with a high interobserver reproducibility in histological evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Purification and characterization of hypoxia-inducible factor 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

High expression of HIF1a is a predictor of clinical outcome in patients with pancreatic ductal adenocarcinomas and correlated to PDGFA, VEGF, and bFGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Hypoxia-inducible factor 1α expression and its clinical significance in pancreatic cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Hypoxia-inducible factors: central regulators of the tumor phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

PanIN-specific regulation of Wnt signaling by HIF2α during early pancreatic tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viability

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Disrupting proton dynamics and energy metabolism for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

MUC1 mucin stabilizes and activates hypoxia-inducible factor 1 alpha to regulate metabolism in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Strengthened glycolysis under hypoxia supports tumor symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Reductive glutamine metabolism is a function of the α-ketoglutarate to citrate ratio in cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Hypoxia inducible factor-1 mediates effects of insulin on pancreatic cancer cells and disturbs host energy homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Silencing of the hypoxia-inducible cell death protein BNIP3 in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Upregulation of BNIP3 by 5-aza-2'-deoxycytidine sensitizes pancreatic cancer cells to hypoxia-mediated cell death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Overview on how oncogenic Kras promotes pancreatic carcinogenesis by inducing low intracellular ROS levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Loss of SOD3 (EcSOD) Expression Promotes an Aggressive Phenotype in Human Pancreatic Ductal Adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Modulation of reactive oxygen species in pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Distribution of Gemcitabine Is Nearly Homogenous in Two Orthotopic Murine Models of Pancreatic Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Turning anti-ageing genes against cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

BH3-only protein Noxa is a mediator of hypoxic cell death induced by hypoxia-inducible factor 1alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

BCL-xL is a target gene regulated by hypoxia-inducible factor-1{alpha}.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Gemcitabine resistance is associated with epithelial-mesenchymal transition and induction of HIF-1α in pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Targeting multidrug resistance in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

An undesired effect of chemotherapy: gemcitabine promotes pancreatic cancer cell invasiveness through reactive oxygen species-dependent, nuclear factor κB- and hypoxia-inducible factor 1α-mediated up-regulation of CXCR4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Metastasis: from dissemination to organ-specific colonization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Mechanisms of motility in metastasizing cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Microenvironmental regulation of metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Epithelial-mesenchymal transitions in development and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Epithelial-mesenchymal transitions in development and pathologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Tube travel: the role of proteases in individual and collective cancer cell invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

High-degree tumor budding and podia-formation in sporadic colorectal carcinomas with K-ras gene mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Tumor budding as a strong prognostic indicator in invasive ampullary adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Tumour budding is a strong and independent prognostic factor in pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Tumor hypoxia correlates with metastatic tumor growth of pancreatic cancer in an orthotopic murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Loss of FOXA1/2 is essential for the epithelial-to-mesenchymal transition in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Hedgehog signaling regulates hypoxia induced epithelial to mesenchymal transition and invasion in pancreatic cancer cells via a ligand-independent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Nuclear factor-κB-dependent epithelial to mesenchymal transition induced by HIF-1α activation in pancreatic cancer cells under hypoxic conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Hypoxia induces EMT in low and highly aggressive pancreatic tumor cells but only cells with cancer stem cell characteristics acquire pronounced migratory potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Intermittent blood flow in solid tumours--an under-appreciated source of 'drug resistance'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Role of the Hypoxia-inducible factor-1 alpha induced autophagy in the conversion of non-stem pancreatic cancer cells into CD133+ pancreatic cancer stem-like cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Hypoxia induces tumor aggressiveness and the expansion of CD133-positive cells in a hypoxia-inducible factor-1α-dependent manner in pancreatic cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Transcriptional upregulation of MT2-MMP in response to hypoxia is promoted by HIF-1α in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

HIF1 contributes to hypoxia-induced pancreatic cancer cells invasion via promoting QSOX1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Hypoxia-inducible factor-1α regulates chemotactic migration of pancreatic ductal adenocarcinoma cells through directly transactivating the CX3CR1 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Hypoxia activates the hedgehog signaling pathway in a ligand-independent manner by upregulation of Smo transcription in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Cancer-associated stromal fibroblasts promote pancreatic tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Pancreatic stellate cells: partners in crime with pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Stromal biology and therapy in pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Tumor-stroma interactions in pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Hypoxia stimulates pancreatic stellate cells to induce fibrosis and angiogenesis in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Hypoxia triggers hedgehog-mediated tumor-stromal interactions in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Unraveling the therapeutic potential of the Hedgehog pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

The role of pancreatic stellate cells in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Triptolide reverses hypoxia-induced epithelial-mesenchymal transition and stem-like features in pancreatic cancer by NF-κB downregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Everolimus for advanced pancreatic neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Extracellular superoxide dismutase suppresses hypoxia-inducible factor-1α in pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Differential toxic mechanisms of 2-deoxy-D-glucose versus 2-fluorodeoxy-D-glucose in hypoxic and normoxic tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

The wonders of 2-deoxy-D-glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Efficacy of 2-halogen substituted D-glucose analogs in blocking glycolysis and killing "hypoxic tumor cells".

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Systemic administration of 3-bromopyruvate reveals its interaction with serum proteins in a rat model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Systemic delivery of microencapsulated 3-bromopyruvate for the therapy of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Targeting hypoxia in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1117386

10.1586/17474124.2016.1117386

21 January 2018

Identifiers

DOI

1 reference

4 September 2017

1 reference